drugset / Trial / NCT07333469
A Clinical Study of HX111 in Patients With Advanced Solid Tumor and Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The study will consist of a Phase I dose-escalation and Phase IIa dose-expansion component. Phase I dose-escalation phase will establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D),and evaluate the preliminary antitumor activity of HX111.
Timeline
- Start
- 2026-01-19
- Primary completion
- 2028-01-19
- Completion
- 2030-01-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HX111 | Unknown | 0.5 mg/kg | — |
| Subject | HX111 | Unknown | 2.5 mg/kg | — |